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Abstract - GRK5 is a multifunctional protein that is 
able to move within the cell in response to various 
stimuli to regulate key intracellular signaling from 
receptor activation, on plasmamembrane, to gene 
transcription, in the nucleus. Thus, GRK5 is 
involved in the development and progression of 
several pathological conditions including cancer. 
Several reports underline the involvement of GRK5 
in the regulation of tumor growth even if they appear 
controversial. Indeed, depending on its subcellular 
localization and on the type of cancer, GRK5 is able 
to both inhibit cancer progression, through the 
desensitization of GPCR and non GPCR-receptors 
(TSH, PGE2R, PDGFR), and induce tumor growth, 
acting on non-receptor substrates (p53, AUKA and 
NPM1). All these findings suggest that targeting 
GRK5 could be an useful anti-cancer strategy, for 
specific tumor types. In this review, we will discuss 
the different effects of this kinase in the induction 
and progression of tumorigenesis, the molecular 
mechanisms by which GRK5 exerts its effects, and 
the potential therapeutic strategies to modulate them.  
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I. INTRODUCTION 
 
GRKs (G-protein-coupled- receptor kinases) are a 
family of serine/threonine kinases traditionally 
known for their ability to recognize and 
phosphorylate agonist-activated G-protein-coupled 
receptors (GPCRs), leading to their desensitization 
[1]. In particular, the agonist-dependent 
conformational change of the receptor renders the 
latter available for GRK-mediated-phosphorylation, 
leading to G-protein-uncoupling, to the increase of 
GPCR affinity for arrestins and clathrin-dependent 
receptor internalization [2]. In this manner, GRKs 
act as crucial negative regulators of a variety of 
GPCRs, including adrenergic receptors, muscarinic 
receptors, dopamine, opioid and chemokine 
receptors [3-6]. Seven subtypes of GRKs (GRK1–7) 
have been identified to date, subdivided into three 
groups depending on sequence homology: rhodopsin 
kinases or visual GRK subfamily (GRK1 and 
GRK7), the β-adrenergic receptor kinases subfamily 
(GRK2/GRK3) and the GRK4 subfamily (GRK4, 
GRK5 and GRK6) [1, 7, 8]. GRKs share a common 
basic structural architecture [1], characterized by a 
well-conserved central catalytic domain (∼270 aa), a 
variable-length carboxyl-terminal domain (∼105–
230 aa) and an N-terminal domain (∼185 aa) which 
includes a Regulator of G protein Signaling 
Homology (RH) domain [8, 9]. Several studies 
demonstrate that the expression and activity of 
GRKs are impaired in many pathological conditions 
[10-12]. Although GRKs are highly selective for 
agonist activated GPCRs, others substrates have 
been identified in the last decade. Indeed, GRKs are 
able to phosphorylate non-GPCR receptors, such as 
PDGF-receptor [13], and non–receptor substrates, 
such as tubulin, synucleins, the β-subunit of the 
epithelial Na+ channel, insulin receptor substrate 1 
(IRS-1), NF-kB inhibitor (IkBα), and others soluble 
substrates [14-18]. Moreover, GRKs regulate 
intracellular signaling also in a phosphorylation-
independent manner, through the direct interaction 
with a variety of proteins involved in cellular 
signaling and trafficking [19-21]. Thus GRKs are 
multifunctional proteins able to regulate key cellular 
processes, from receptor activation to nuclear 
transcription [22], in different cellular compartments 
[23-25] , due to their ability to move within the cell 
in response to stimuli [25, 26].  
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II. G-PROTEIN COUPLED RECEPTOR KINASE 
5 
 
Among GRKs, GRK5 is one of the most studied 
since it is involved in several pathologic conditions 
[27-29]. Indeed, GRK5 is up-regulated in failing 
human myocardium [29-31], and its over-expression 
in the heart reduced cardiac β-AR responsiveness 
[32, 33]. Several reports underline the involvement 
of GRK5 in the regulation of glucose metabolism 
[30, 34, 35]. Indeed, it has been shown that, the 
overexpression of GRK5 enhances the 
internalization of Glucagon Receptor, a GPCR that 
mediates hyperglycaemic effects of glucagon in 
Diabetes [36, 37]. Accordingly, GRK5 gene deletion 
in mice, leads to impaired glucose tolerance and 
insulin sensitivity [30]. GRK5 attenuates 
atherosclerosis through multiple cell type-specific 
mechanisms including desensitization of Tyrosine 
Kinase receptors, such as macrophage CSF-1R, and 
the SMC platelet-derived growth factor receptor-β 
(PDGFR) [28]. Several reports show that GRK5 is 
also involved in Parkinson disease, due to its ability 
to phosphorylate the α-synuclein, modulating 
dopamine-up-take [38, 39]. 
GRK5 effects on the regulation of intracellular 
signaling depend on cell type, stimuli, and kinase 
localization within the cell. GRK5 binds to cellular 
membranes through C-terminal polybasic domain 
and an N-terminal phosphatidyl- inositol -4-5-
bisphosphate (PIP2) binding site [40, 41]. While 
GRK2 and GRK3 are primarily cytoplasmic and are 
targeted to plasma membrane by binding Gβγ 
subunits through their C-terminal pleckstrin 
homology domain, GRK5 constitutively binds 
phospholipids and displays preferential membrane 
localization [19]. However, GRK5 is also able to 
localize into the nucleus, through means of 
functional nuclear localization sequence (NLS), that 
allows the kinase to enter the nucleus and bind DNA 
in vitro [24]. Such nuclear localization is regulated 
by intracellular calcium levels. Indeed, the activation 
of M3MR increases intracellular calcium levels and 
activates the calcium sensor protein, CaM, which on 
turn binds the N-terminal domain of GRK5 
promoting its nuclear export [24].  
GRK5 shuttles between the cytosol and the nucleus 
and regulates the activities of transcription factors at 
different levels. Indeed, GRK5 phosphorylates 
histone deacetylase 5 (HDAC5), a repressor of 
myocyte enhancer factor 2 (MEF2), leading to 
nuclear export of HDAC5 and activation of MEF2 
transcription activity, in cardiac hypertrophy [42]. 
Moreover, in a model of Parkinson disease, the 
nuclear accumulation of GRK5 inhibits gene 
transcription of apoptosis regulator bcl-2, probably 
increasing HDAC activity [43].  
Moreover, GRK5 regulates the activity of the 
transcription factor NFκB [44]. Since it binds the 
inhibitory protein of NFκB, IκBα, by means of the 
RH domain (GRK5-RH) and stabilize the complex 
IκBα/NFκB in the nucleus, thus inhibiting NFκB 
transcriptional activity. The intracardiac injection of 
an adenovirus encoding the N-terminal domain of 
GRK5, AdGRK5-NT, reduces left ventricular 
hypertrophy by inhibiting NFB-dependent 
hypertrophic gene expression [45]. Furthermore, 
Hullmann et al. showed that GRK5, acting in a 
kinase independent manner, is a facilitator of NFAT 
activity [46]. All this findings suggest that GRK5, 
trafficking within the cell, regulates key cellular 
processes that are involved in the development and 
progression of several pathological conditions.  
GRK5, in addition to the above described roles in 
the cytoplasm and recently discovered activities in 
the nucleus, is now also reported herein to be 
functionally localized to centrosomes [47]. The 
localization of this kinase within the centrosome 
suggests another way by which GRKs can affect 
cellular processes. 
 
III. ROLE OF GRK5 IN CANCER 
 
It’s known that the oncogenic phenotype derives 
from diverse genetic alterations that cause 
constitutive activation or a loss of function of 
proteins, such as the loss of allelic heterozygosity 
[48, 49]. Importantly, chromosome translocation of 
the 10q24 region has been specifically observed in 
several tumors, such as thyroid adenoma and glioma 
[50], suggesting that alteration of some genes in this 
region could affect the development of tumors. 
Since GRK5 maps on chromosome 10, at q24 region 
[51], it is likely that alteration of GRK5 gene, could 
be involved in certain thyroid or glia tumors. Several 
reports underline the involvement of GRK5 in the 
regulation of tumor growth. However, the effectS of 
GRK5 on cancer cell proliferation are controversial 
depending on its subcellular localization and on the 
type of cancer. In this review, we discuss these 
different effects of GRK5 on tumor progression, and 
the different molecular mechanisms by which GRK5 
exerts these effects. Moreover, we will debate about 
the potential therapeutic strategies for cancer 
focused on GRK5 as main target.  
 
A. GRK5 inhibits tumor growth by regulating      
GPCR signaling 
 
G protein-coupled receptors (GPCRs), the largest 
family of cell surface proteins involved in signal 
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transduction, have recently emerged as key 
regulators of tumor growth and metastasis [52]. 
Their role in the tumorigenic process depends on the 
specific tumor type and is due to their direct 
interaction or cross-talk with others receptors (i.e. 
EGF receptors) [52-54]. Thus, the pharmacological 
manipulation of these receptors is becoming an 
attractive goal for the development of novel 
strategies to target tumor progression and metastasis. 
In this context, it is not surprising that GRK5, could 
be a molecular target of these novel therapeutic 
strategies. Several studies show that GRK5 may be a 
negative regulator of cancer cell proliferation, 
mainly through its ability to desensitize GPCR on 
plasma membrane. Tsai et al. have shown that in 
colon cancer cells HCT116, the expression of 
Tazarotene-induced gene 1 (TIG-1), a putative 
tumor suppressor, inhibits cell proliferation by 
inducing GRK5 expression in response to PGE2 [55, 
56]. TIG1 suppresses PGE2-stimulated cell 
proliferation through inhibition of β-catenin 
pathway, and this effect is mediated by GRK5, since 
it is ameliorated by GRK5 siRNA. Moreover, the 
over-expression of GRK5 suppressed PGE2-
stimulated β-catenin activation in a dose dependent 
manner in HCT116 and DLD-1 cells (Fig.1).  
Also in thyroid cancer cells, GRK5 has negative 
effects on tumor growth, due to its ability to down-
regulate GPCRs activity, in particular TSH-receptor 
activity [57]. The TSH receptor, is a major 
determinant of thyroid function and most of  
 
 
 
Figure 1: TIG-1 inhibits PGE2-dependent cell proliferation 
through the induction of GRK5 expression 
PGE2 binds and stimulates EP2, a GPCR, that 
activates PI3K; PI3K converts PIP2 in PIP3, that 
recruits PDK1 and AKT on plasmamembrane. 
PDK1 phosphorylates and activates AKT, that 
inhibits GSK3β, blocking β-catenin degradation and 
promoting cell proliferation.  
TIG-1 induces GRK5 over-expression which on turn 
inhibits EP2, blocking its signaling transduction with 
an inhibitory effect on cell proliferation.  
the TSH effects on proliferation and differentiation 
of thyroid cells are mediated by cAMP via an 
adenylyl- cyclase-activating Gs protein [58]. Indeed, 
several thyroid cancer types (DTC) have high levels 
of cAMP compared with normal thyroid tissue 
(NTT), and it has been demonstrated that this is 
associated with a reduction of the expression of 
GRK5 gene and protein levels. The data suggest that 
GRK5 is involved in the regulation process of TSH-
stimulated cAMP response in human DTC. Thus, it 
is likely to speculate that GRK5 down-regulation of 
GPCRs could be one of the mechanisms that ensure 
a proliferative advantage to cancer cell, because the 
loss of GRK5 activity, allows the cell to escape to a 
control mechanism of the cellular growth.  
GRK5 inhibits cancer cell proliferation in the 
Kaposi’s sarcoma [59]. In tissues of patients with 
Kaposi’s sarcoma, human herpesvirus -8 (KSHV) is 
consistently present. This gamma-herpesvirus may 
be involved in the pathogenesis of primary effusion 
(or body cavity-based) lymphomas [60] and 
Kaposi’s sarcoma (KS) [61], and it contains a gene 
that encodes a G protein–coupled receptor (KSHV-
GPCR) [62]. KSHV-GPCR is constitutively 
activated and its expression stimulates cell 
proliferation and causes transformation of mouse 
fibroblasts [63, 64]. The co-expression of GRK5 
inhibits KSHV-GPCR–induced cell proliferation and 
prevents transformation of rodent fibroblasts. 
Altogether, these findings support the proof of 
concept that GRK5 inhibits tumor growth in 
different cancer cells, through the phosphorylation 
of GPCR (Fig. 2) on plasmamembrane.  
 
B. Non-GPCR receptors and tumor growth  
 
Besides GPCRs, other receptor signaling are 
involved in the development of cancer, such as 
Thirosine-kinase receptors (TRK) and Frizzled 
family receptors [65, 66]. It is known that the 
activation of these receptors is regulated by GRK5  
 
 
 
Figure 2 GRK5 inhibits tumor growth through phosphorylation 
of GPCR A) GPCRs are activated through the interaction with a 
specific ligand. The activated receptor, through G-protein, 
stimulates proliferative signaling. B-C) GRK5 interacts (B) and 
phosphorylates  (C) GPCR, promoting un-coupling of G-protein 
and inhibition of proliferative signaling. 
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in different cell types [67, 68], although it was never 
explored in cancer cells. Thus, it is likely that GRK5 
could regulate tumor growth also through the 
regulation of TRK and Frizzled receptors. This 
could be the inspiration for future studies.  
 
C. GRK5 promotes tumor growth 
 
Besides the above described inhibitory effect of 
GRK5 on tumor growth when it is located on plasma 
membrane, in other compartments GRK5 interacts 
with several intracellular molecules and modulates 
their stability and activity, thus favoring tumor 
development and progression. Here we report the 
effect of GRK5 on some of these molecules. 
 
D. GRK5 regulates p53 
 
An evidence that suggests the ability of GRK5 to 
promote tumorigenesis, is its ability to inhibits p53, 
participating to the regulation of genome integrity. 
p53 is a crucial tumor suppressor that induces cell 
cycle arrest or apoptosis in response to diverse 
stresses, and its function is regulated primarily at the 
level of protein stability through post-translational 
modifications such as phosphorylation and 
acetylation [69, 70]. It is well established that the 
misregulation of p53 level or activity compromises 
cellular apoptotic response and contributes to 
tumorigenesis [71, 72]. Chen et al have shown that 
GRK5 phosphorylates p53 at Thr-55 and promotes 
its degradation, thus inhibiting p53-mediated 
apoptosis both in vitro (Fig.3), in cultured human 
osteosarcoma cells, and in vivo [73]. In particular, 
GRK5 knockout mice show abnormal p53 levels and 
enhanced susceptibility in response to irradiation. 
These findings support an essential role of GRK5 to 
restrict p53 and protect genomic stability under 
physiological and pathological conditions. 
Moreover, this role of GRK5 was confirmed in 
humans, mice and bovines indicating that, it is 
conserved across species. How GRK5 coordinates 
with other p53 regulators in response to various  
 
 
 
Figure 3GRK5 promotes p53 degradation GRK5 interacts with 
and phosphorylates p53 leading to an increase of p53-MDM2 
interaction, which on turn induces poli-ubiquitination and 
degradation of p53. 
genotoxic stresses to maintain genomic stability 
remains to be further elucidated, but it is clear that 
GRK5 also acts as stimulator of pro-tumoral effect 
in the cell, representing a potential target to attenuate 
resistance to radiation that characterizes some types 
of cancer.  
 
E. GRK5 phosphorylates moesin  
 
Cancer metastasis involves the cell local invasion 
and migration so that detached cells from the 
primary tumor mass can colonize distant organs. 
Among the molecular mediators of cancer cell 
migration and invasion, moesin is part of ERM 
complex (Ezrin-Radixin-Moesin) that links 
membrane components to actin cytoskeleton, 
regulating cytoskeleton remodeling and cell 
adhesions [74, 75]. Altered expression or 
intracellular distribution of ERMs has been linked to 
tumor metastasis. In particular, ERM proteins 
interact with membrane through an N-terminal 
FERM domain, and with actin through C-terminal 
domain. The intra-molecular interaction between 
these two domains masks several binding sites 
leading to inactivation of ERM proteins [74]. The 
phosphorylation of ERM proteins by different 
kinases interrupts this intra-molecular interaction 
and activates the ERM-complex [74]. Chakraborty at 
al demonstrated that GRK5 colocalizes with moesin 
on the plasma membrane, catalyzes its 
phosphorylation at T66 residue, and regulates 
cellular distribution of moesin promoting actin 
remodeling and, then, invasion and metastasis of 
PC3 cells (Fig.4)[76]. Moreover, in a xenograft 
model of human prostate cancer, GRK5 silencing 
reduced tumor growth, invasion and metastasis [76]. 
Taken together, these results propose GRK5 as a key 
contributor to the growth and metastasis of prostate 
cancer. 
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F. GRK5 phosphorylates nucleophosmin, NPM1 
 Cancer cells are able to escape from normal 
mechanisms of cell cycle control; indeed, many 
“oncosuppressors” are genes that act as cell cycle – 
checkpoint, such as Rb and p53. These genes, 
determine a cell cycle arrest when the cellular 
genome has accumulated irreversible damages, or 
when the extracellular environment is not conducive 
to cell replications (i.e. without 
 
 
 
Figure 4GRK5 promotes cytoskeleton remodeling inducing 
cancer cell migration and invasion. In the inactive form of 
ERM-complex, the COOH and NH domains interact, 
determining a close conformation of the complex. GRK5 
phosphorylates an ERM-component (Moesin), interrupting this 
intra-molecular interaction and activating ERM-complex. In the 
activated form of the ERM- complex, the COOH domain 
interacts with cytoskeleton while the NH domain interacts with 
plasma membrane, inducing cytoskeleton remodeling and, 
consequently, cell migration and invasion. 
growth factors). Genetic alterations that determine 
loss of function of these genes are typical of cancer 
cell [77]. Among the regulator of cell cycle 
progression in cancer, GRK5 could represent a 
candidate molecule, given its nuclear localization 
and the identification of new nuclear substrates of 
this kinase. Indeed, it has been demonstrated that in 
the nucleus GRK5 interacts with and phosphorylates 
nucleophosmin (NPM1)[78], a multifunctional 
protein involved in the regulation of cell cycle, 
centrosomal duplication and apoptosis, that is 
overexpressed in several cancer types [79]. NPM1 
function is regulated primarily through 
phosphorylation by PLK1, that leads to the 
protection from cell death [80]; Indeed, the inhibitor 
of PLK1, that induces apoptosis, is used in the 
treatment of several cancers, including esophageal 
cancer [81], neuroblastomas [82], and others [83]. 
GRK5 phosphorylates NPM1 at Ser-4, a site shared 
with PLK1, suggesting the possibility of an interplay 
between GRK5 and PLK1, in the regulation of 
NPM1. In particular GRK5-depleted cells were more 
sensitive to apoptosis induced by PLK1 inhibition, 
while cells with high GRK5 levels exhibited reduced 
sensitivity to PLK1 inhibition [78]. GRK5-
dependent regulation of cell sensitivity to PLK1 
inhibitors is an important finding with potential 
implications in combined therapies with these 
inhibitors. Indeed, it is likely to speculate that in 
subjects with higher levels of GRK5, the 
administration of PLK1 inhibitor could be 
ineffective and that therapeutic approach based on 
both PLK1 and GRK5 inhibition, could be more 
effective than PLK1 inhibition alone, in certain 
cancer types characterized by hyperactivation of 
PLK1- signaling.  
Several other reports support the association 
between GRK5 activity and cell cycle regulation. In 
particular in Hela cells, breast cancer cells and also 
in non-trasformated cells, GRK5 localizes in 
centrosomes during interphase and promotes G2/M 
transition thus affecting cell cycle progression [47]. 
The knock down of GRK5 leads to G2/M arrest, 
even if the mechanism through which GRK5 exerts 
this effect is not clear yet.  
 
IV. TARGETING GRK5 AS POTENTIAL 
THERAPEUTIC STRATEGY FOR CANCER 
 
The regulation of the expression and activity of 
GRKs has yielded promising results in the treatment 
of multiple diseases, from heart failure and diabetes 
to cancer and inflammatory diseases, in several 
animal models and cell culture systems [17, 25, 84, 
85]. Given these findings, a selective inhibitor of 
GRK2 has been synthesized and tested both in 
cardiovascular diseases and tumors [18, 86-88]. On 
the opposite, whereas its inhibition strongly 
correlates with cardiac protection or regression of 
some tumors, to date no available specific inhibitors 
have been designed and synthesized for GRK5. To 
date, only one inhibitor of GRK5 has been recently 
reported [89], the amlexanox, that directly binds the 
active site of the kinase in a manner that mimics the 
adenine ring of ATP, and significantly inhibits 
MEF2 transcriptional activity, in association with 
the inhibition of GRK5 in cells. However, this 
inhibitor is not strictly selective for GRK5, and it 
has not been tested in cancer yet. It could be useful 
to synthesize specific inhibitor of GRK5 for the 
treatment of those tumors characterized, for 
instance, by low levels of the pro-apoptotic protein 
p53, to promote cell cycle arrest and apoptosis.  
On the opposite, given the anti-tumoral effect of 
GRK5 acting on GPCRs, the induction of GRK5 
levels could be the effective strategy for the 
treatment of GPCR-dependent tumors. Several 
compounds are available that induce CREB activity 
[90], a transcription factor that regulate the 
expression of several genes, including GRK5 gene. 
Thus the use of these compounds could be effective 
to induce GRK5 expression in cancer.  
Little is known about the nuclear effects of GRK5 in 
cancer. It is likely that GRK5 could enter the 
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nucleus and regulate the activity of transcription 
factors which on turn induce the expression of pro- 
and anti-apoptotic genes. It has been shown that 
GRK5 inhibits HDAC5 in the nucleus, promoting 
MEF2 expression in cardiac myocytes [22, 42]. 
Given the main role of this enzymes in cancer 
progression and the use of HDAC inhibitors as anti-
cancer drugs [91, 92], it could be interesting to 
evaluate such phenomenon also in tumor cells. 
An innovative strategy has been proposed that is 
specific for cancer and is based on a competitive 
interaction with GRK5 cytosolic substrates rather 
than inhibition of its activity, the TAT-RH peptide 
[93]. TAT-RH binds IBα, the inhibitory protein of 
NFB, thus stabilizing IBα– NFB complex and 
blocking NFB transcriptional activity. In cultured 
tumor cells, different dosages of TAT-RH reduced 
cell survival and increased apoptosis. In BALB/c 
mice, the anti-proliferative effects of TAT-RH 
appear to be dose-dependent and highest dose 
completely inhibits tumor growth. Thus, TAT-RH is 
a promising compound for the treatment of those 
tumors which are NFB dependent [94]. 
 
V. CONCLUSIONS AND FUTURE 
PROSPECTIVE 
 
GRK5 is a multifunctional protein that is able to 
move within the cell in response to various stimuli to 
regulate key intracellular signaling from receptor 
activation, on plasmamembrane, to gene transcription, 
in the nucleus. Thus, GRK5 is involved in the 
development and progression of several pathological 
conditions such as cardiac hypertrophy and failure, 
diabetes and cancer.  
The proof of concept that GRK5 is involved in the 
regulation of cancer progression derives from the 
discovery that GRK5 was part of a subset of gene 
targets required for mitotic progression in human 
cancer cells. However, its role in tumor growth is 
still complex and ambiguous, since GRK5 exerts 
opposite effects, depending on tumor cell type and 
kinase localization within the cell. Indeed, when the 
kinase is localized at plasma membrane, it often 
exerts an anti-tumoral effect, attenuating growth-
associated pathway through its ability to desensitize 
GPCR and non GPCR-receptors (TSH, PGE2R, 
PDGFR). On the contrary, when GRK5 moves to 
others compartments, such as cytosol and nucleus, it 
promotes tumor growth acting on non receptor- 
substrates, such as p53, AUKA and NPM1.  
Given these different effects of GRK5 on tumor 
growth, targeting GRK5 could be an useful anti-
cancer strategy, for specific tumor types. In this 
context, further studies will be needed to better 
define the nuclear effects of GRK5 and the 
possibility to regulate its subcellular localization in 
order to regulate its functions within the tumor cell 
as necessary.    
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